FDA Accepts Unicycive Therapeutics’ Resubmitted NDA
The FDA accepted the company’s resubmitted New Drug Application for oxylanthanum carbonate. Unicycive shares rose 5% to $4 in morning trade.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA Accepts Unicycive’s Oxylanthanum Carbonate NDA Resubmission
Unicycive Therapeutics said the FDA accepted its resubmitted new drug application for oxylanthanum carbonate and set a PDUFA date of March 25, 2027.